FENC — Fennec Pharmaceuticals Inc

Fennec Pharmaceuticals Inc (FENC) is a biotechnology company listed on NASDAQ. It is led by Jeffrey S. Hackman, based in 68 TW Alexander Drive, Research Triangle Park, NC, United States, 27709, with about 35 employees. Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation, Inc. for evaluation of clinical utility of sodium thiosulfate injection in reducing the risk of ototoxicity in adolescent, young adult, and adult cancer patients receiving cisplatin-based treatment; and Norgine Pharma UK Limited. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

Latest reported FENC revenue for 2025-09-30 was $12.5M. Net income was -$5.0M. Revenue was up 29.1% from 2025-06-30 to 2025-09-30. FENC currently screens at market cap $302.2M.

Use this FENC page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the FENC quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the FENC SEC filings page. Lician reads the product cache first so this HTML stays unique to Fennec Pharmaceuticals Inc even when a live quote feed is slow.